Humans vs microbes: the ASM goes to war
01 October, 2002 by Graeme O'NeillMicrobiology is in ferment, says Dr Jan Tennent, and the next decade is likely to see major gains in the perennial war between humans and their microbial nemeses -- viruses, bacteria and parasites.
ES Cell refocuses cell line marketing strategy
27 September, 2002 by Pete YoungSingapore-based company ES Cell International is changing the marketing strategies for its human embryonic stem cell lines because of researchers' reluctance to part with intellectual property.
Stem cell Bill moves to the Senate
26 September, 2002 by Pete YoungThe stage has been for a final Senate debate on a Bill permitting research on embryonic human stem cells following the legislation's passage by a three-to-one margin in the House of Representatives.
Parliamentary debate continues on stem cells
26 September, 2002 by Graeme O'NeillBehind the headlines, hype and huff-and-puff politics surrounding the therapeutic use of stem cells, there is fierce debate even among the experts over which research route holds the greater promise: adult, or embryonic?
Funds lagging for new stem cell centre
25 September, 2002 by Pete YoungA skeleton administrative staff is at work on the $43.5 million National Stem Cell Centre even though Federal government has yet to sign a deed of agreement for the controversial research institute.
Politics, not science, is key to stem cell issues: Reeve
20 September, 2002 by Melissa TrudingerThe hope of millions of patients was riding on politics far more than science, paralysed actor and stem cell research advocate Christopher Reeve told delegates in a taped keynote speech at the Stem Cells 2002 conference this week.
Stem cell debate: now IVF is under threat
17 September, 2002 by Melissa TrudingerThe Federal House of Representatives agreed in principle on Monday night to pass the Research Involving Embryos Bill, voting 103 in favour to 36 against. But debate continued on the controversial bill as the first of a series of amendments was proposed.
New doubts cast on adult stem cell potential
06 September, 2002 by Melissa TrudingerResearchers at Stanford University Medical Center in the US have reported that they failed in attempts to coax adult blood-forming stem cells in mice into forming tissues other than blood and immune cells.
From footy to neuroscience: CogState branches out
05 September, 2002 by Melissa TrudingerA Melbourne company, whose test to measure cognitive abilities counts AFL teams among its customers, is branching out into biotech to develop neuroscience therapeutics.
Singapore govt awards grant to Agenix subsidiary
30 August, 2002 by Pete YoungA Singapore government decision to award a major grant to a subsidiary of Australian listed biotech Agenix is being labelled a "great vote of confidence" by Agenix CEO Don Home.
Stem cell Bill split but debate continues
30 August, 2002 by Pete YoungThe stem cell debate is likely to reach new levels of intensity in the wake of the vote splitting legislation permitting embryonic stem cell research from a bill outlawing human cloning.
Interview: DeVore takes the reins at stem cell centre
26 August, 2002 by Melissa TrudingerA few months ago, Dianna DeVore was an associate director of patents at Irish pharmaceutical company Elan in San Francisco. Now she's the chief operating officer of the National Centre for Stem Cells, Australia's first biotechnology Centre of Excellence.
Top scientist backs both adult and embryonic cell research
22 August, 2002 by Melissa TrudingerLeading scientist Catherine Verfaillie has told a briefing in Melbourne it was "unfortunate" that her work was held up as evidence that embryonic stem cell research was unnecessary.
Get it together on stem cells, warns Macfarlane
21 August, 2002 by Iain ScottIndustry Minister Ian Macfarlane last night warned scientists that the real threat to the future of stem cell research in Australia was because of researchers' conflicting goals.
Cellestis posts fourfold jump in revenue
09 August, 2002 by Tanya HollisInfectious disease detection test developer Cellestis has posted a greater than fourfold jump in revenue to end the full year at $583,000.
